Ratings Intco Medical Technology Co., Ltd.

Equities

300677

CNE100003456

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 17/07/2025			5-day change	1st Jan Change
29.71 ^CNY	-0.20%		+10.53%	+17.52%

07-01	Tranche Update on Intco Medical Technology Co., Ltd.'s Equity Buyback Plan announced on September 19, 2024.	CI
04-28	Intco Medical Technology's Q1 Net Profit Up 48.1% Y/Y	RE

Summary: Intco Medical Technology Co., Ltd.

According to MSCI, the company's ESG score for its industry is good.

Highlights: Intco Medical Technology Co., Ltd.

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2027.
The company's attractive earnings multiples are brought to light by a P/E ratio at 12.59 for the current year.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Ratings Chart: Intco Medical Technology Co., Ltd.

Source: Surperformance

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Global Valuation (Composite)	Capi.($)
INTCO MEDICAL TECHNOLOGY CO., LTD.	-	2.64B
COLOPLAST A/S		21.19B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED		3.77B
WINNER MEDICAL CO., LTD.	-	3.19B
KANGJI MEDICAL HOLDINGS LIMITED		1.3B
TOP GLOVE CORPORATION BHD.		1.27B
HARTALEGA HOLDINGS		1.14B
NAKANISHI INC.		1.09B
Average		4.45B
Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes